Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
about
Development of enzalutamide for metastatic castration-resistant prostate cancer.Cardiovascular toxicities of systemic treatments of prostate cancer.Dose considerations for anti-cancer drugs in metastatic prostate cancer.Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
P2860
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Safety of enzalutamide in pati ...... anded access in North America.
@en
Safety of enzalutamide in pati ...... anded access in North America.
@nl
type
label
Safety of enzalutamide in pati ...... anded access in North America.
@en
Safety of enzalutamide in pati ...... anded access in North America.
@nl
prefLabel
Safety of enzalutamide in pati ...... anded access in North America.
@en
Safety of enzalutamide in pati ...... anded access in North America.
@nl
P2093
P2860
P356
P1433
P1476
Safety of enzalutamide in pati ...... anded access in North America.
@en
P2093
Carl A Olsson
Carl Dmuchowski
Enzalutamide Expanded Access Study Investigators
Eric Winquist
Frank Perabo
Margaret A Foley
Mark Scholz
Mohammad Hirmand
P2860
P304
P356
10.1002/PROS.22965
P577
2015-02-14T00:00:00Z